Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:38 2025-07-15 pm EDT			After hours 08:00:00 pm
81.52 ^USD	-2.57%		82.25	+0.90%

Jul. 15	Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million	RE
Jul. 14	Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill	CI

CDC's vaccine advisory committee to vote on RSV, flu shots

Published on 06/18/2025 at 11:16

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million	Jul. 15	RE
Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill	Jul. 14	CI
Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally	Jul. 14	RE
Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention	Jul. 14	MT
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	Jul. 11	RE
Global markets live: Tesla, Nvidia, Google, BP, Nissan…	Jul. 11
MERCK : Jefferies raises TP after Verona acquisition	Jul. 11
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	Jul. 11	MT
Wall Street Waits to Hear the Numbers	Jul. 11
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating	Jul. 11	MT
Merck: Jefferies raises TP after Verona acquisition	Jul. 11
Merck: FDA approval for Bravecto Quantum	Jul. 11
Merck: seeks FDA approval for new HIV treatment	Jul. 11
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S.	Jul. 10	DJ
Merck Animal Health Gets FDA Approval for Bravecto Quantum	Jul. 10	MT
Fda approves Bravecto Quantum, a long-acting injectable for dogs 6 months and older	Jul. 10	RE
Morgan Stanley Adjusts Price Target on Merck to $98 From $99, Maintains Equalweight Rating	Jul. 10	MT
Global markets live: Nvidia, Tesla, Blackstone, BMW, Samsung…	Jul. 10
AI Mania Masks Trade War Risks	Jul. 10
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection	Jul. 10	CI
Merck Says FDA Accepts for Review New Drug Application for Doravirine/Islatravir to Treat HIV-1 Infection in Adults	Jul. 10	MT
Merck : FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection	Jul. 10	DJ
U.S. FDA accepts new drug application for Merck's doravirine/islatravir	Jul. 10	RE
Deals of the day-Mergers and acquisitions	Jul. 10	RE
Formycon tops SDax with news on FYB206	Jul. 10	DP

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

06:15am - International AIDS Society Conference

More about the company